StonvexLoading…
StonvexStonvexStonvexCore line items from CRI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-01-03 | Annual 2024 2024-12-28 | Annual 2023 2023-12-30 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.90B | $2.84B | $2.95B | $3.21B |
Operating Income | $143.93M | $254.73M | $323.40M | $379.17M |
Net Income | $91.80M | $185.51M | $232.50M | $250.04M |
EPS (Diluted) | $2.53 | $5.12 | $6.24 | $6.34 |
Total Assets | $2.57B | $2.43B | $2.38B | $2.44B |
Total Liabilities | $1.64B | $1.58B | $1.53B | $1.64B |
Cash & Equivalents | $487.07M | $412.93M | $351.21M | $211.75M |
Free Cash Flow OCF − CapEx | $68.63M | $242.62M | $469.27M | $48.00M |
Shares Outstanding | 36.43M | 36.04M | 36.55M | 37.69M |